Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comprehensive Profiling of Mutations to Influenza Virus PB2 That Confer Resistance to the Cap-Binding Inhibitor Pimodivir.

Viruses - 22 Jun 2021

Soh Y Q Shirleen, Malone Keara D, Eguia Rachel T, Bloom Jesse D

Abstract excerpt

Antivirals are used not only in the current treatment of influenza but are also stockpiled as a first line of defense against novel influenza strains for which vaccines have yet to be developed. Identifying drug resistance mutations can guide the clinical deployment of the antiviral and can additionally define the mechanisms of drug action and drug resistance. Pimodivir is a first-in-class inhibitor of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to A549 Cells
Share to Birds
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Influenza A virus

Share to Influenza in Birds

Share to Pyridines

Share to Pyrimidines

Share to Pyrroles

Source

Open in PubMed Open full text

Identifiers

PMID: 34206520
DOI: 10.3390/v13071196
PMCID: PMC8310130

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comprehensive Profiling of Mutations to Influenza Virus PB2 That Confer Resistance to the Cap-Binding Inhibitor Pimodivir.PMID 34206520Read ↗

Comprehensive profiling of mutations to influenza virus PB2 that confer resistance to the cap-binding inhibitor pimodivirSemantic proximity Read ↗

Genotypic and phenotypic characterization of influenza A viral variants in study participants treated with pimodivir in the phase 2b TOPAZ study.Semantic proximity Read ↗

Susceptibility of widely diverse influenza a viruses to PB2 polymerase inhibitor pimodivirSemantic proximity Read ↗

Structural and Thermodynamic Analysis of the Resistance Development to Pimodivir (VX-787), the Clinical Inhibitor of Cap Binding to PB2 Subunit of Influenza A Polymerase.Semantic proximity Read ↗

Comprehensive assessment of amino acid substitutions in the trimeric RNA polymerase complex of influenza A virus detected in clinical trials of baloxavir marboxilSemantic proximity Read ↗

Preparing for the Next Influenza Season: Monitoring the Emergence and Spread of Antiviral ResistanceSemantic proximity Read ↗

Next-Generation Sequencing: An Eye-Opener for the Surveillance of Antiviral Resistance in Influenza.Semantic proximity Read ↗

Impact of the polymerase acidic protein E199K substitution in influenza A viruses on baloxavir susceptibilitySemantic proximity Read ↗

PA-E18G substitution in influenza A virus confers resistance to ZX-7101, a cap-dependent endonuclease inhibitorSemantic proximity Read ↗

Antiviral susceptibility of clade 2.3.4.4b highly pathogenic avian influenza A(H5N1) viruses isolated from birds and mammals in the United States, 2022Semantic proximity Read ↗

Identification of Novel Influenza Polymerase PB2 Inhibitors Using a Cascade Docking Virtual Screening Approach.Semantic proximity Read ↗

Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.